1. Home
  2. CASH vs LQDA Comparison

CASH vs LQDA Comparison

Compare CASH & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CASH
  • LQDA
  • Stock Information
  • Founded
  • CASH 1954
  • LQDA 2004
  • Country
  • CASH United States
  • LQDA United States
  • Employees
  • CASH N/A
  • LQDA N/A
  • Industry
  • CASH Major Banks
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CASH Finance
  • LQDA Health Care
  • Exchange
  • CASH Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • CASH 1.9B
  • LQDA 1.7B
  • IPO Year
  • CASH N/A
  • LQDA 2018
  • Fundamental
  • Price
  • CASH $75.30
  • LQDA $25.95
  • Analyst Decision
  • CASH Buy
  • LQDA Strong Buy
  • Analyst Count
  • CASH 2
  • LQDA 10
  • Target Price
  • CASH $91.00
  • LQDA $31.40
  • AVG Volume (30 Days)
  • CASH 190.3K
  • LQDA 3.4M
  • Earning Date
  • CASH 07-28-2025
  • LQDA 08-12-2025
  • Dividend Yield
  • CASH 0.27%
  • LQDA N/A
  • EPS Growth
  • CASH 4.46
  • LQDA N/A
  • EPS
  • CASH 6.92
  • LQDA N/A
  • Revenue
  • CASH $733,796,000.00
  • LQDA $19,322,000.00
  • Revenue This Year
  • CASH $14.15
  • LQDA $190.73
  • Revenue Next Year
  • CASH $5.99
  • LQDA $421.01
  • P/E Ratio
  • CASH $10.89
  • LQDA N/A
  • Revenue Growth
  • CASH 5.46
  • LQDA 30.20
  • 52 Week Low
  • CASH $62.79
  • LQDA $8.26
  • 52 Week High
  • CASH $86.00
  • LQDA $26.65
  • Technical
  • Relative Strength Index (RSI)
  • CASH 42.79
  • LQDA 79.56
  • Support Level
  • CASH $71.95
  • LQDA $19.02
  • Resistance Level
  • CASH $77.04
  • LQDA $26.65
  • Average True Range (ATR)
  • CASH 1.97
  • LQDA 1.53
  • MACD
  • CASH 0.07
  • LQDA 0.64
  • Stochastic Oscillator
  • CASH 33.40
  • LQDA 92.88

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: